ONO-2160 is a new drug being developed for the treatment of Parkinson's Disease. It also includes carbidopa, which is the same as is included in Sinemet. ONO-2160 is an L-dopa pro-drug, which means that once absorbed it is converted into L-dopa.
An open study clinical trial was carried out on people with Parkinson's Disease in which ONO-2160 and carbidopa was compared to the use of L-dopa and carbidopa, which is what is in Sinemet.
Patients were primarily evaluated using the Unified Parkinson's Disease Rating Scale Part III, a Parkinson's disease symptom diary, and analysis of adverse events. Pharmacokinetic analysis of plasma levodopa concentration was also performed. ONO-2160 and carbidopa therapy stabilized the plasma concentration of L-dopa better than L-dopa with carbidopa. No adverse events with safety concerns were observed.
The combination of ONO-2160 and carbidopa produced a prolonged and stable plasma L-dopa concentration whilst also reducing the Parkinson's Disease symptom scores. The combination was well tolerated with no safety concerns. The results suggest an improved method of administering L-dopa.
Reference : eNeurologicalScience [2018] 13 : 8-13 (M.Nomoto, M.Nagai, N.Nishikawa, R. Ando, Y.Kagamiishi, K.Yano, S.Saito, A.Takeda)
Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/30294682
http://www.viartis.net/parkinsons.disease/news/181018.pdf
No comments:
Post a Comment